What Just Happened — And Why It Matters

On March 20, 2026, Novo Nordisk's core Indian patent for semaglutide — the molecule behind Ozempic (diabetes) and Wegovy (weight loss) — expired. Within hours, a wave of Indian pharmaceutical companies launched their own versions at dramatically lower prices.

To put this in perspective: branded Ozempic costs ₹8,800–₹11,175 per month in India. Wegovy costs up to ₹16,400/month. The cheapest generic now available is ₹1,290/month — a 90% price drop. More than 40 manufacturers are expected to launch generics under over 50 brand names this year.

For my patients at Nirvana Clinic, this changes everything. Semaglutide was always clinically excellent — it was just unaffordable for most Indians. That barrier has collapsed overnight.

Complete Generic Semaglutide Price Comparison — April 2026

This table covers every major launch as of April 2026. Prices are MRP per month for the starting dose. Prices may vary by pharmacy, city, and stock availability.

Sources: Company filings, CNBC, Bloomberg, Business Standard, Fierce Pharma, Pharmarack data. Prices are approximate MRP and may vary.

Vial vs Pen — Which Should You Choose?

This is the question every patient asks me. The answer depends on your comfort level, budget, and whether you have someone to help with injections.

Multi-dose vial (₹1,290–₹1,750/month)

The cheapest option by far. A vial contains multiple doses — you draw each week's dose using a syringe. Natco and Glenmark offer this format. It requires more skill: you need to draw the correct volume, store the vial properly in the refrigerator, and use a fresh syringe each time. I recommend this only for patients who are comfortable with syringes or have a family member (often an NRI's parent's caregiver) who can administer it.

Pre-filled disposable pen (₹1,800–₹4,500/month)

Click, dial the dose, inject. No measuring, no drawing. Alkem, Dr. Reddy's, and Sun Pharma offer these. More expensive than vials but dramatically easier to use. For most of my patients, this is the right balance of cost and convenience.

Reusable multi-dose pen (₹2,200/month)

Zydus offers a reusable pen where you replace cartridges. Better value over months of use. The pen itself is sturdier and allows dose adjustment. This is my preferred format for patients on long-term therapy — the per-month cost is competitive and the device quality is good.

What I Am Actually Prescribing at Nirvana Clinic — April 2026

Patients want to know: "Doctor, which generic do you trust?" Here is my honest answer.

I am currently prescribing from three manufacturers:

For cost-sensitive patients: Alkem's Semasize (₹1,800/month, pre-filled pen). It is the cheapest pen-based option with DCGI approval for both diabetes and weight management. Alkem has strong backward integration — they manufacture their own API, which gives me confidence in supply consistency.

For patients who prioritise device quality: Zydus's Semaglyn or Mashema (~₹2,200/month, reusable pen). The reusable pen is better engineered and allows precise dose adjustment. I like the multi-dose format for long-term patients who will be on semaglutide for 6+ months.

For patients who want established brand credibility: Sun Pharma's Noveltreat or Sematrinity (~₹3,000–₹3,400/month). Sun Pharma is the world's largest generics company. Some patients feel more comfortable with that name recognition, and the pre-filled pen design is well-executed.

I have stopped recommending branded Ozempic for new prescriptions unless the patient specifically prefers it and cost is not a concern. The molecule is identical. The generics are DCGI-approved after clinical trials. The price difference — up to ₹9,000/month — is not justified by any clinical superiority.

The Dangers of Self-Medicating With Generic Semaglutide

Here is what can go wrong without medical oversight:

Wrong dose titration: Semaglutide must be started at a low dose (0.25mg weekly) and gradually increased over 8–16 weeks. Starting at a higher dose causes severe nausea, vomiting, and dehydration. I have already seen three patients in the past week who started at 1mg because the pharmacy sold them that strength — all three had to stop the drug due to intolerable GI side effects.

Missing underlying conditions: Before prescribing semaglutide, I check HbA1c, fasting insulin, kidney function, liver function, thyroid panel (semaglutide is contraindicated in patients with a personal or family history of medullary thyroid cancer), and lipid profile. Skipping these tests can be medically dangerous.

Muscle loss instead of fat loss: Without nutritional monitoring, patients on GLP-1 drugs lose muscle mass along with fat. This is especially dangerous in older patients. I track body composition, not just weight, and adjust protein intake accordingly.

Counterfeit products: With 50+ brands flooding the market, counterfeit or substandard products are inevitable. Buy only from verified pharmacies. If the price seems too good to be true, it probably is.

Who Should Consider Generic Semaglutide?

Good candidates: Type 2 diabetes patients with HbA1c above 7% despite current treatment. Patients with BMI above 30 (or above 27 with comorbidities like diabetes, hypertension, or sleep apnoea). Patients with PCOD-related metabolic syndrome. Patients who have tried lifestyle modification for 6+ months without adequate results.

Not suitable for: Pregnant or breastfeeding women. Patients with personal or family history of medullary thyroid carcinoma or MEN2. Active pancreatitis. Severe kidney disease (eGFR below 15). Patients with a history of severe GI conditions.

Requires careful assessment: Patients on insulin (dose adjustment needed). Patients with retinopathy (rapid glucose improvement can worsen it). Elderly patients (higher risk of dehydration and muscle loss). Patients with a history of gallbladder disease.

What About Mounjaro (Tirzepatide)?

With semaglutide generics crashing in price, patients now ask: "Should I take cheap semaglutide or stick with Mounjaro?"

Mounjaro (tirzepatide by Eli Lilly) is a dual GIP/GLP-1 agonist that shows greater weight loss in clinical trials. However, it remains significantly more expensive — Mounjaro has no generic in India yet and its patent is intact. Monthly costs are typically ₹8,000–₹15,000 depending on dose.

My clinical approach: for most patients, I now start with generic semaglutide. If the response at the maximum tolerated dose is inadequate after 3–6 months, I consider switching to Mounjaro. The cost savings from starting with generic semaglutide (potentially ₹6,000–₹13,000/month cheaper) are substantial — and many patients achieve their targets on semaglutide alone.

Frequently Asked Questions